Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07655284 · ClinicalTrials.gov registry record · Phase 3

STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy

A Phase 3 study, sponsored by Brigham and Women's Hospital.

Not yet
Registry status
Phase 3
Development phase
190
Enrollment target

NCT07655284: Clinical Trial Phase 3 study, sponsored by Brigham and Women's Hospital.

NCT07655284 is a Phase 3 study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 190 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07655284, a Phase 3 study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.

NOT YET RECRUITING
Registry status
Phase 3
Development phase
190 participants
Enrollment target

Study Summary

Radical Cystectomy (RC) remains the gold standard for localized muscle-invasive bladder cancer (MIBC); however, use of ureteral stents at time of surgery remains controversial without level 1 evidence to comment on risks or benefits of their use. RC complications commonly include urinary tract infections (UTIs), pyelonephritis, ureteroileal leakage and stenosis, and can occur with either ileal conduit or orthotopic neobladder diversions. Traditionally, ureteral stents are thought to support anastomotic healing and reduce the risk of anastomotic leakage and strictures; however, emerging evidence from retrospective studies suggests that stent use may paradoxically increase rates of postoperative morbidity. This randomized, multicenter and prospective study aims to compare 30-day postoperative complication rates between stented and non-stented urinary diversions in patients undergoing RC for MIBC, in both ileal conduit or neobladder with either robotic or open approaches.

Interventions

  • DEVICE ureteral stents
  • DEVICE no ureteral stent

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2026-09-01
Est. Completion 2029-08-31
Phase Phase 3
Brigham and Women's Hospital

937 total trials

What is known before NCT07655284 opens enrollment

NCT07655284 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 2 interventions - of which ureteral stents is the first listed.

NCT07655284 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07655284 about?

NCT07655284 is a clinical study titled "STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy". Radical Cystectomy (RC) remains the gold standard for localized muscle-invasive bladder cancer (MIBC); however, use of ureteral stents at time of surgery remains controversial without level 1 evidence to comment on risks or benefits of their use. RC complications commonly include urinary tract infec...

What is the current status of trial NCT07655284?

This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2026-09-01. Estimated completion is 2029-08-31.

What interventions are being tested in trial NCT07655284?

The interventions under investigation include: ureteral stents (DEVICE), no ureteral stent (DEVICE).

Who is sponsoring clinical trial NCT07655284?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07655284's enrollment target sits among peer trials

190 1402nd of 2000 higher than 593 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03257033 · 190 participants · Phase 3

    Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

  • NCT03642028 · 190 participants · Phase 4

    Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

  • NCT04015609 · 190 participants · NA

    Psychotherapy Intervention for Latinos With Advanced Cancer

  • NCT04284397 · 190 participants · Early Phase 1

    Identification of Critical Thermal Environments for Aged Adults

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07655284, the US trial registry maintained by the National Library of Medicine. NCT07655284 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.